Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia
- Author
- MUSCETTOLA, G1 ; BARBATO, G2 ; PAMPALLONA, S3 ; CASIELLO, M1 ; BOLLINI, P3
[1] University Federico II, Department of Neuroscience and Interhuman Communication, Section of Psychiatry, Napoli, Italy
[2] Second University of Naples, School of Psychology, Napoli, Italy
[3] forMed, Statistics for Medicine, Evolène, Switzerland - Source
Journal of clinical psychopharmacology. 1999, Vol 19, Num 3, pp 203-208 ; ref : 43 ref
- CODEN
- JCPYDR
- ISSN
- 0271-0749
- Scientific domain
- Pharmacology drugs; Psychology, psychopathology, psychiatry
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Association morbide Chimiothérapie Dyskinésie Epidémiologie Extrapyramidal syndrome Facteur risque Homme Neuroleptique Prévalence Psychotrope Santé publique Tardif Toxicité Traitement Trouble psychiatrique Italie Encéphale pathologie Mouvement involontaire Système nerveux central pathologie Système nerveux pathologie Trouble neurologique Europe
- Keyword (en)
- Concomitant disease Chemotherapy Dyskinesia Epidemiology Extrapyramidal syndrome Risk factor Human Neuroleptic Prevalence Psychotropic Public health Late Toxicity Treatment Mental disorder Italy Cerebral disorder Involuntary movement Central nervous system disease Nervous system diseases Neurological disorder Europe
- Keyword (es)
- Asociación morbosa Quimioterapia Disquinesia Epidemiología Extrapiramidal síndrome Factor riesgo Hombre Neuroléptico Prevalencia Psicotropo Salud pública Tardío Toxicidad Tratamiento Trastorno psiquiátrico Italia Encéfalo patología Movimiento involuntario Sistema nervosio central patología Sistema nervioso patología Trastorno neurológico Europa
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U01 Toxicity: nervous system and muscle
- Discipline
- Drugs toxicity and drug intoxications Toxicology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1785175
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"203\";s:8:\"\u0000*\u0000epage\";s:3:\"208\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"MUSCETTOLA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:10:\"BARBATO, G\";i:1;s:13:\"PAMPALLONA, S\";i:2;s:11:\"CASIELLO, M\";i:3;s:10:\"BOLLINI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"203\";s:8:\"\u0000*\u0000epage\";s:3:\"208\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"MUSCETTOLA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:10:\"BARBATO, G\";i:1;s:13:\"PAMPALLONA, S\";i:2;s:11:\"CASIELLO, M\";i:3;s:10:\"BOLLINI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"203\";s:8:\"\u0000*\u0000epage\";s:3:\"208\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"MUSCETTOLA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:10:\"BARBATO, G\";i:1;s:13:\"PAMPALLONA, S\";i:2;s:11:\"CASIELLO, M\";i:3;s:10:\"BOLLINI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"203\";s:8:\"\u0000*\u0000epage\";s:3:\"208\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"MUSCETTOLA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:10:\"BARBATO, G\";i:1;s:13:\"PAMPALLONA, S\";i:2;s:11:\"CASIELLO, M\";i:3;s:10:\"BOLLINI, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"Extrapyramidal syndromes in neuroleptic-treated patients : Prevalence, risk factors, and association with tardive dyskinesia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
